Sign In

Article Information

  • Too Costly to Defend: Who Is Benefited From the U.S. Supreme Court’s Recent Holdings Concerning Biotechnology Patent Disputes?

    Justice Scalia’s recent holdings on behalf of the Supreme Court in Merck KGaA v. Integra Lifesciences I, Ltd. and MedImmune Inc. v. Genentech, Inc. have had a grave impact on biotechnology research. These cases represent the two sides of the same coin and, therefore, should be examined together rather than separately.